Patents by Inventor Ian P. Conner

Ian P. Conner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Goblet cell replacement therapy
    Patent number: 10561710
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 18, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
  • GOBLET CELL REPLACEMENT THERAPY
    Publication number: 20180333460
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 22, 2018
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
  • Goblet cell replacement therapy
    Patent number: 9895419
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 20, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
  • GOBLET CELL REPLACEMENT THERAPY
    Publication number: 20170000852
    Abstract: Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
    Type: Application
    Filed: January 20, 2015
    Publication date: January 5, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Cecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner